Goodwin Procter advised Fulcrum Therapeutics on the deal.Fulcrum Therapeutics, Inc. (Nasdaq: FULC) announced its underwritten public offering of 9,615,384 shares of its common stock at a…
Fulcrum Therapeutics’ $125 Million Public Offering of Common Stock
